Clinical Context
A typical patient is an adult with severe eosinophilic asthma or eosinophilic chronic rhinosinusitis refractory to standard inhaled corticosteroids and bronchodilators who is scheduled to receive subcutaneous benralizumab therapy. The patient presents to an outpatient infusion or injection clinic, allergy/immunology office, or pulmonology clinic for administration of J0517 (benralizumab, 1 mg). The clinical workflow includes verification of patient identity and insurance, review of indications and recent clinical status (exacerbation frequency, oral corticosteroid use, blood eosinophil count), documentation of any prior biologic therapy and allergic reactions, and assessment of injection site and vitals. The medication is prepared as the appropriate mg dose (per product dosing schedule), administered subcutaneously, and the patient is observed for immediate hypersensitivity or injection-site reaction per office protocol (commonly 30 minutes for first dose, shorter for maintenance doses if tolerated). Nursing documents lot number, expiration, dose administered, route (subcutaneous), site (e.g., right deltoid), and applicable modifier if required by the payer. Follow-up includes scheduling the next dose per dosing interval and documenting clinical response and any adverse events.